New IBD drug shows promise in Real-World study
Disease control
Completed
This study tested VedAryo® (vedolizumab) in 150 people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). The goal was to see if the drug safely reduces symptoms over 52 weeks. Participants received the drug and were monitored for side effects and improvemen…
Sponsor: AryoGen Pharmed Co. • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC